Daniel Dauch

Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies.

Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies.

Journal: Journal of medicinal chemistry
Published: March 24, 2025

Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity.

Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity.

Journal: Cell reports
Published: February 13, 2025

Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence.

Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence.

Journal: Cancer immunology, immunotherapy : CII
Published: July 08, 2024

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

Journal: Gastro hep advances
Published: July 03, 2024

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

Journal: Journal of medicinal chemistry
Published: April 11, 2024

Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation.

Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation.

Journal: Nature metabolism
Published: November 27, 2023

Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities.

Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities.

Journal: Journal of medicinal chemistry
Published: May 25, 2023

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer.

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer.

Journal: Nature cancer
Published: April 19, 2023

MYC determines lineage commitment in KRAS-driven primary liver cancer development.

MYC determines lineage commitment in KRAS-driven primary liver cancer development.

Journal: Journal of hepatology
Published: December 27, 2022

Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Journal: Nature medicine
Published: February 19, 2022

HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1.

HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1.

Journal: Cancers
Published: January 04, 2022

Exploiting lipotoxicity for the treatment of liver cancer.

Exploiting lipotoxicity for the treatment of liver cancer.

Journal: British journal of cancer
Published: April 07, 2021
Showing 1-12 of 29

Last Updated: 09/26/2026